Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arvinas Holding Company LLC

8.78
+0.17902.08%
Volume:1.92M
Turnover:16.68M
Market Cap:603.75M
PE:-3.17
High:8.88
Open:8.53
Low:8.21
Close:8.60
Loading ...

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

GlobeNewswire
·
Yesterday

Arvinas Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

Insider Monkey
·
09 Apr

Arvinas Is Maintained at Buy by Truist Securities

Dow Jones
·
09 Apr

Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating

MT Newswires Live
·
09 Apr

BUZZ-Arvinas hits all-time low following Piper Sandler PT cut

Reuters
·
08 Apr

Arvinas Price Target Maintained With a $81.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Apr

Guggenheim Keeps Their Buy Rating on Arvinas Holding Company (ARVN)

TIPRANKS
·
07 Apr

U.S. RESEARCH ROUNDUP-Apple, Tesla, Walmart

Reuters
·
07 Apr

Arvinas Inc : Piper Sandler Cuts Target Price to $24 From $67

THOMSON REUTERS
·
07 Apr

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Benzinga
·
05 Apr

Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2

MT Newswires Live
·
04 Apr

Arvinas presents first-in-human data from ARV-102 trial

TIPRANKS
·
04 Apr

Arvinas Inc -Data Demonstrate That Arv-102 Was Well Tolerated

THOMSON REUTERS
·
04 Apr

Arvinas Inc -Arv-102 Achieved Central and Peripheral Lrrk2 Reduction Indicating Substantial Lrrk2 Protein Degradation in Healthy Volunteers

THOMSON REUTERS
·
04 Apr

Arvinas Presents First-in-Human Data for Investigational Oral Protac Arv-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral Lrrk2 Degradation

THOMSON REUTERS
·
04 Apr

Arvinas-Expects to Complete Enrollment and Present Initial Data From Ongoing Sad Cohort of Phase 1 Clinical Trial in Patients With Pd in 2025

THOMSON REUTERS
·
04 Apr

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Simply Wall St.
·
03 Apr

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

THOMSON REUTERS
·
27 Mar

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

GlobeNewswire
·
27 Mar